TP1033

TP1033 is a cannabinoid-based pharmaceutical candidate being developed by Tetra Pharm Technologies for the treatment of Alzheimer's Disease. The drug utilizes the company's proprietary drug delivery technology, designed to enhance the bioavailability and therapeutic profile of cannabinoids. TP1033 is intended to modulate the endocannabinoid system, which is increasingly recognized for its role in regulating neuroinflammation, oxidative stress, and protein clearance in the brain. By targeting cannabinoid receptors, TP1033 aims to provide neuroprotective effects and potentially slow the progression of cognitive decline associated with Alzheimer's pathology.